Authors
  • Xavier Pi-Sunyer, MD, MPH is Professor of Medicine at Columbia University College of Physicians and Surgeons in New York City and is co-Director of the NIH-supported New York Obesity Nutrition Research Center. After receiving his BA in 1955 from Oberlin College, Dr. Pi-Sunyer went on to complete an MD from Columbia's College of Physicians and Surgeons in 1959 and an MPH from Harvard University School of Public Health in 1963. He has served as president of the American Diabetes Association, the American Society for Clinical Nutrition, and the North American Association for the Study of Obesity, as well as a Councilor of the Society for Experimental Biology and Medicine. He has been a Fellow of the Fogarty International Center of the National Institutes of Health, a member of the Institute of Medicine’s Task Forces on Opportunities in the Nutrition and Food Sciences, on Medical Nutrition Therapy and on Dietary Reference Intakes on Macronutrients. He served on the 2005 and 2010 U.S. Dietary Guidelines Advisory Committee. He recently completed a term on the FDA Science Board Advisory Committee to the Commissioner. He chaired the committee of the U.S. National Heart, Lung, and Blood Institute that researched and defined the federal government’s guidelines for the prevention and treatment of obesity in 1998 and has just concluded membership on the Task Force that completed the AHA/ACC/Obesity Society Guidelines on Obesity in 2013. His research focus is on carbohydrate and lipid metabolism, obesity and diabetes. He has over 450 peer-reviewed publications. He is on the Steering Committees of the NIH-sponsored Diabetes Prevention Program, the LookAhead , the Life-Moms and the GRADE trials of the NIDDK.
    • Endocrinology, Diabetes and Metabolism
    • Clinical Pathology
    Metabolic Medicine Physician, University College Dublin
    Metabolic Medicine Physician, University College Dublin
    • Head of Pathology at University College Dublin
    Professor Carel le Roux (MBChB, FRCP, FRCPath and a PhD) graduated from medical school in Pretoria South Africa, completed his Senior House Officer training at Barts and The London Hospital, his SpR training in metabolic medicine at the Hammersmith Hospitals and his PhD at Imperial College London. He was appointed as Senior Lecturer and later Reader at Imperial and accepted a Chair as Head of Pathology at University College Dublin in 2011. He received a President of Ireland Young Researcher Award, Clinician Scientist Award from the National Institute Health Research in the UK and a Wellcome Trust Clinical Research Fellowship amongst others. The focus of his research is primarily concerned with increased mortality and morbidity associated with obesity and its related diseases. A better mechanistic understanding of how the “gut talks to the brain” will allow safer and more effective treatments to be used in future. To this end the role of gut hormones, bile acids and changes in food preference are areas of interest.
    • Obesity Medicine
    • Director, Nutrition and Metabolic Research Center; Director, Center for Weight Management at Scripps Clinic
    Ken Fujioka is director of the Nutrition and Metabolic Research Center and the Center for Weight management in La Jolla California at the Scripps Clinic. His time is divided equally between clinical research and clinical practice. Research includes diets, medications, bariatric surgery, medical devices, web based weight loss programs, and outcomes in obesity treatment. The Nutrition and Metabolic Research Center has completed over 100 clinical trials in obesity related areas. The Center for Weight Management is a referral based multispecialty center that includes endocrinologists, surgeons, psychologist, dietitians, exercise physiologist, and nurse practitioners. The multispecialty clinic sees over a 1000 patients a month. It is a recognized Center of Excellence and attempts to treat all forms of obesity, morbid obesity, and eating disorders. Dr. Fujioka has also worked for the Medical board for the state of California as an expert witness. In 1997 he was asked to define the standard of care in the treatment of obesity. He has published original research, as well as chapters of books and reviews. He has worked with multiple government agencies and pharmaceutical companies on drug development and use in clinical practice.
    • Endocrinology, Diabetes and Metabolism
    • Obesity Medicine
    • Professor of Medicine & Honorary Consultant Physician at University Hospital, Aintree, Liverpool
    John Wilding leads Clinical Research into Obesity, Diabetes and Endocrinology at the University of Liverpool, UK. He trained in medicine in Southampton and at the Hammersmith Hospital, London where he also undertook three years laboratory-based research into the neurobiology of obesity and diabetes. He has worked at University Hospital Aintree, Liverpool since 1996 and as Professor of Medicine since 2005. He has published over two hundred papers, chapters and review articles related to his clinical and laboratory research interests in type 2 diabetes and obesity. His clinical research focuses on the pathophysiology of obesity and diabetes and evaluation of new treatments. He is Chair of the UK National Clinical Research Network Metabolic and Endocrine Speciality Group. He leads specialist services for severe obesity at University Hospital Aintree – designated as a Centre for Obesity Management by the European Association for the Study of Obesity.
    • Endocrinology, Diabetes and Metabolism
    • Obesity Medicine
    • Professor of Medicine, Biochemistry and Molecular Biology at University of Calgary Cumming School of Medicine
    Dr. David Lau is Professor of Medicine, Biochemistry and Molecular Biology at the University of Calgary Cumming School of Medicine. He is currently the Editor-in-Chief of the Canadian Journal of Diabetes, and President, Canadian Association of Bariatric Physicians and Surgeons, and President of Obesity Canada. Dr. Lau is a practising endocrinologist who specializes in obesity diabetes, and lipid disorders. His research interests include fat cell biology in health and obesity, development of insulin resistance in obesity and diabetes, and cellular mechanisms of diabetic vascular complications. He is also involved in population health and clinical research programmes in diabetes, obesity and lipid disorders. Dr. Lau has published over 150 scientific papers in peer-reviewed medical journals, periodicals and books. He was Chair of the evidence-based Obesity Canada Clinical Practice Guidelines (CPG) Steering Committee and Expert Panel, and lead author of the 2007 CPG publication in the Can. Med. Assoc. Journal. Dr. Lau was an Expert Panel member of the 2013 evidence-based Canadian Diabetes Association Clinical Practice Guidelines (he also served as an expert member for the 1998, 2003, 2008 updates), and a member of the primary panel expert committee on the 2012 Canadian Cardiovascular Society Guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult as well as the expert panel of the 2009 Canadian Cardiovascular Society lipid guidelines. Dr. Lau was honored as the top 20 notable Calgarians, and top 50 Albertans in 2004 for his exemplary contributions to improve the health of Albertans.
    • Obesity Medicine
    International Medical Director at Novo Nordisk A/S
    International Medical Director at Novo Nordisk A/S
    • Project Director at Novo Nordisk
    Dr Jensen is currently International Medical Director, heading up the Saxenda® Medical & Science team in Global Development at Novo Nordisk A/S. She has extensive experience from all stages of clinical drug development within diabetes and obesity. During the past 4½ years she had the overall clinical responsibility for execution, reporting, submission and approval of liraglutide 3.0 mg (Saxenda®) for weight management and most recently lead the team preparing the FDA Advisory Committee meeting for Saxenda®. Prior to joining Novo Nordisk in 2007, Dr Jensen spent several years doing clinical and basic metabolic research, including 2 years as a postdoctoral fellow at Joslin Diabetes Center/Harvard Medical School in Boston, Massachusetts, and 3½ years at Steno Diabetes Center, exploring the mechanisms underlying early programming of disease. She has authored more than 25 articles in international peer-reviewed articles.
Want to stay updated? Follow Discussion & Ask Your Question